{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-453730","form_type":"8-K/A","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2026-11-09T21:39:21+00:00","discovered_at":"2026-11-09T21:40:00.265273+00:00","generated_at":"2026-11-09T21:40:09.791028+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zymeworks completes Theravance merger; pro forma 9M26 net income $11.8M on $321.2M revenue","bullets":["Merger completed Sept 23, 2026: each Theravance share converted into $17.00 cash plus one CVR tied to ampreloxetine proceeds and sales.","Consideration for shares $887.2M plus $28.4M equity awards; total $915.6M, reduced by $355.2M cash acquired, net $560.4M.","Financing includes $350M OMERS non-recourse notes at 8.25%, maturing Dec 31, 2036, secured by YUPELRI assets with 75% of YUPELRI profit-share cash flows assigned.","Pro forma 9M 2026 revenue $321.2M and net income $11.8M ($0.15 diluted EPS); FY2025 pro forma revenue $213.4M and net loss $43.7M ($0.58).","Preliminary purchase accounting: $415.4M YUPELRI product rights, $96.7M TRELEGY milestone receivable, $104.4M goodwill, $91.6M unrecognized tax benefits."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-453730","json":"https://secwatch.observer/filing/0001193125-26-453730.json","markdown":"https://secwatch.observer/filing/0001193125-26-453730.md","text":"https://secwatch.observer/filing/0001193125-26-453730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526453730/0001193125-26-453730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312526453730/d79244d8ka.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-09T21:40:09.791028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}